Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 12,500 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 12,500 shares of Enliven Therapeutics stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $20.61, for a total value of $257,625.00. Following the sale, the insider now directly owns 1,002,688 shares of the company’s stock, valued at approximately $20,665,399.68. This trade represents a 1.23 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $21.08 on Friday. The business’s 50 day moving average is $21.31 and its two-hundred day moving average is $23.76. Enliven Therapeutics, Inc. has a 1-year low of $15.96 and a 1-year high of $30.03. The stock has a market capitalization of $1.03 billion, a P/E ratio of -11.09 and a beta of 1.04.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, March 13th. The company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.07. The business had revenue of $0.03 million for the quarter. As a group, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Institutional Trading of Enliven Therapeutics

A number of large investors have recently modified their holdings of the company. Barclays PLC lifted its holdings in Enliven Therapeutics by 295.8% during the third quarter. Barclays PLC now owns 56,217 shares of the company’s stock worth $1,435,000 after buying an additional 42,012 shares during the period. Geode Capital Management LLC lifted its holdings in Enliven Therapeutics by 9.9% during the third quarter. Geode Capital Management LLC now owns 750,208 shares of the company’s stock worth $19,164,000 after buying an additional 67,813 shares during the period. Ally Bridge Group NY LLC purchased a new stake in Enliven Therapeutics during the third quarter worth $5,998,000. Patient Square Capital LP purchased a new stake in Enliven Therapeutics during the third quarter worth $2,313,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Enliven Therapeutics by 10.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock valued at $6,520,000 after purchasing an additional 24,043 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. BTIG Research assumed coverage on Enliven Therapeutics in a report on Friday, December 13th. They set a “buy” rating and a $42.00 price target on the stock. HC Wainwright lifted their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a report on Friday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Enliven Therapeutics currently has an average rating of “Buy” and an average target price of $38.75.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.